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Abstract
Background: Lactic acid bacteria (LAB) are attractive tools to deliver therapeutic molecules at
the mucosal level. The model LAB Lactococcus lactis has been intensively used to produce and
deliver such heterologous proteins. However, compared to recombinant lactococci, lactobacilli
offer some advantages such as better survival in the digestive tract and immunomodulatory
properties. Here, we compared different strategies to optimize the production of bovine β-
lactoglobulin (BLG), a major cow's milk allergen, in the probiotic strain Lactobacillus casei BL23.
Results: Using a nisin-inducible plasmid system, we first showed that L. casei BL23 strain could
efficiently secrete a reporter protein, the staphylococcal nuclease (Nuc), with the lactococcal signal
peptide SPUsp45 fused to its N-terminus. The fusion of SPUsp45 failed to drive BLG secretion but led
to a 10-fold increase of intracellular BLG production. Secretion was significantly improved when
the synthetic propeptide LEISSTCDA (hereafter called LEISS) was added to the N-terminus of the
mature moiety of BLG. Secretion rate of LEISS-BLG was 6-fold higher than that of BLG alone while
intracellular production reached then about 1 mg/L of culture. The highest yield of secretion was
obtained by using Nuc as carrier protein. Insertion of Nuc between LEISS and BLG resulted in a
20-fold increase in BLG secretion, up to 27 μg/L of culture. Furthermore, the lactococcal nisRK
regulatory genes were integrated into the BL23 chromosome. The nisRK insertion allowed a
decrease of BLG synthesis in uninduced cultures while BLG production increased by 50% after nisin
induction. Moreover, modification of the induction protocol led to increase the proportion of
soluble BLG to around 74% of the total BLG production.
Conclusion: BLG production and secretion in L. casei were significantly improved by fusions to a
propeptide enhancer and a carrier protein. The resulting recombinant strains will be further tested
for their ability to modulate the immune response against BLG via mucosal delivery in a cow's milk
allergy model in mice.
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Background
Lactic acid bacteria are non-invasive and non-pathogenic
Gram-positive bacteria with GRAS (generally regarded as
safe) status that are widely used for food-processing and
preservation. In addition, some strains were reported to
exert probiotic effects [1-5]. Using the Nisin-Controlled
Expression (NICE) system, β-lactoglobulin (BLG), a
major cow's milk allergen, was successfully produced in
Lactococcus lactis [6-8]. Administrations of BLG-producing
lactococci to mice has been shown to induce a mucosal
immune response that could partially prevent mice from
a further sensitization to BLG [6,9]. However, L. lactis is
rapidly lysed in each compartment of the digestive tract
[10] whereas other LAB, such as lactobacilli, exhibit a
greater resistance to the gastric environment and a better
survival. Moreover, recent works suggest that some lacto-
bacilli have stronger adjuvant properties than L. lactis
[11]. Lactobacilli may thus appear as more attractive can-
didates to deliver therapeutic proteins to the intestinal
mucosa. Unfortunately, studies with recombinant lacto-
bacilli are often impaired by the lower levels of antigen
production compared to those obtained with L. lactis [12].
This is a major concern since mucosal immune response
depends on the amount of antigen delivered by the bacte-
rial vector [13].
We previously described the construction of L. casei strains
carrying a chromosomal BLG expression cassette inserted
downstream an endogenous constitutive promoter [14].
Such chromosomal insertions led to BLG yields reaching
~2 μg/L of culture. In the present work, we adapted lacto-
coccal tools to improve BLG production in L. casei. For
this purpose, we tested different expression cassettes cod-
ing for BLG in fusion with a carrier protein and/or with a
secretion-enhancer propeptide [15]. We quantified and
analyzed the structure of the recombinant BLG, using two
immunoassays, one specific for BLG in its native confor-
mation and the other specific for reduced and car-
boxymethylated, i.e. denatured, BLG [16]. We thus
succeeded to increase BLG production in L. casei BL23, up
to 1 mg/L of culture. As the two-plasmid NICE system
appeared to be leaky in L. casei BL23, we also integrated
the nisRK genes (necessary for the nisin-inducible expres-
sion of BLG) into the bacterial chromosome. This led to a
1.5-fold increase in BLG production. Finally, we obtained
higher yields of soluble BLG by using different conditions
of nisin-induction.
Results and Discussion
Nuc is efficiently secreted by L. casei
We first investigated the ability of the BL23 strain to pro-
duce and secrete the reporter staphylococcal nuclease
(Nuc, [15]) under the transcriptional control of the nisin-
inducible promoter PnisA. Two plasmids were used (Table
1). The plasmid pNZ9520 encodes the nisRK genes that
are essential for the regulation of the PnisA promoter [17]
and pSEC:Nuc contains a Nuc expression cassette with the
PnisA promoter, the ribosome binding site (RBSUsp45) and
the signal peptide (SPUsp45) of the major lactococcal
secreted protein Usp45 ([18], Fig. 1).
Nuc expression was induced with increasing concentra-
tions of nisin up to 50 ng/mL (Fig. 2). Western blot anal-
ysis of protein extracts from cell lysates and supernatant
fractions showed a dose-response correlation between
nisin concentration and Nuc synthesis. The highest yield
was obtained with 50 ng nisin/mL. We also detected an
increasing release of mature Nuc into the culture medium
in response to nisin induction, showing that SPUsp45 is
functionally recognized and processed by the secretion
machinery of the L. casei BL23 strain. As observed on Fig.
2, the efficient processing of the Nuc precursor is con-
firmed by the small amounts of SPusp45-Nuc found in cell
lysates.
Improved production and secretion of BLG in L. casei
We further investigated BLG production in L. casei with a
construct (on pCYT plasmid, Table 1) targeting intracellu-
lar location and constructs (on pSEC plasmids, Table 1)
encoding different fusion proteins previously designed for
secretion of heterologous proteins in L. lactis [8].
Use of a lactococcal signal peptide
Intracellular production of BLG obtained with the
pCYT:BLG plasmid was relatively low (78 μg/L of culture,
Table 2). The small amount of BLG occasionally detected
in the S fraction was certainly due to BLG release in the
culture medium from lysed cells. Considering that secre-
tion is an efficient way to increase the overall heterolo-
gous protein production in L. lactis [15], we tested
whether enhancement of BLG secretion could improve
BLG yields in L. casei. As SPUsp45-Nuc is efficiently secreted
(Fig. 2), we first investigated the secretion of the precursor
SPUsp45-BLG. Surprisingly, no secreted BLG was detected
in the S fraction of L. casei BL23(pSEC:BLG) (Table 2). In
contrast, we measured a significant enhancement of the
insoluble intracellular BLG concentration (around 706
μg/L). Such effect of SPUsp45 has been already observed for
production of heterologous proteins in L. lactis [6,19]. We
suggest that presence of SPUsp45 sequence improved the
translation of the blg gene but that the resulting protein
was aggregating because of an inefficient recognition of
the hybrid precursor by the secretion machinery. In L.
casei, we thus found 92% of the recombinant BLG in the
Ci fraction. Therefore, BLG in the Cs fraction represented
only 8% of the total BLG production and only 1% of the
soluble BLG exhibited a native conformation.Microbial Cell Factories 2007, 6:12 http://www.microbialcellfactories.com/content/6/1/12
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Use of a propeptide enhancer
The propeptide LEISSTCDA (LEISS) was inserted between
the SPUsp45 and the mature moiety of the BLG. This inser-
tion has been shown to improve secretion of heterologous
proteins produced in L. lactis because of the presence of
negatively charged residues [20]. For example, fusion of
LEISS to BLG led to a 5-fold increase in BLG secretion in
L. lactis [8]. In L. casei, this modification resulted similarly
in a 6-fold increase in BLG secretion, reaching 9 μg/mL of
culture. Total BLG production also increased from 706 μg/
L to 1022 μg/L of culture, but mostly in the Ci fraction. As
observed with SPUsp45-BLG in the Cs fraction, only 1% of
soluble LEISS:BLG protein exhibited a native BLG confor-
mation. However, the proportion of native BLG was sig-
nificantly higher in the supernatant than in the cytoplasm
since 40% of the BLG protein secreted in the culture
medium displayed a native conformation.
Use of a carrier protein
Finally, we evaluated the effect of Nuc as carrier protein.
Nuc protein was shown to improve immunogenicity of
BLG and of a major BLG epitope after oral or subcutane-
ous administrations to mice[7,9]. Moreover, in L. lactis,
insertion of Nuc between LEISS and the mature moiety of
BLG resulted in a 2-fold increase in total BLG production
but in a 4-fold decrease in secretion when compared with
LEISS-BLG [8]. In contrast, Nuc insertion between LEISS
and BLG led to a 3-fold higher secretion in L. casei. Secre-
Table 1: Bacterial strains and plasmids
Strain or plasmid Characteristics Reference
L. casei
BL23 L. casei ATCC 393 (pLZ15-) [26]
BL23(int:nisRK) BL23 containing the nisRK genes integrated to the tRNASer locus; obtained by transformation with pMEC10 This work
Plasmids
pVE3655 Cmr, ori(pWV01), carries the nisin-inducible promoter PnisA
pCYT:BLG Cmr, ori(pWV01), with a DNA fragment encoding the BLG mature moiety expressed under PnisA 
transcriptional control
[6]
pSEC:BLG Cmr, ori(pWV01), with a DNA fragment encoding the precursor SPUsp45-BLG expressed under PnisA 
transcriptional control
[6]
pSEC:LEISS-BLG Cmr, ori(pWV01), with a DNA fragment encoding the precursor SPUsp45-LEISS-BLG expressed under PnisA 
transcriptional control
[8]
pSEC:LEISS-Nuc-BLG Cmr, ori(pWV01), with a DNA fragment encoding the precursor SPUsp45-LEISS-Nuc-BLG expressed under 
PnisA transcriptional control
[8]
pSEC:Nuc Cmr, ori(pWV01), with a DNA fragment encoding the precursor SPUsp45-Nuc expressed under under PnisA 
transcriptional control
[18]
pNZ9520 Emr, nisRK cloned in pIL253 [17]
pMEC10 Emr, integration plasmid containing the nisRK genes and the int-attP cassette for integration to the tRNASer 
locus.
[21]
Dose-dependent nisin induction of staphylococcal nuclease production and secretion Figure 2
Dose-dependent nisin induction of staphylococcal nuclease production and secretion. L. casei BL23 strain was co-
transformed with pSEC:Nuc and pNZ9520 plasmids. Protein extracts were analyzed by immunoblotting using rabbit polyclonal 
anti-Nuc antibodies as described in the Materials and Methods section. Arrows indicate positions of Nuc and its precursor 
form (pre-Nuc).
pre-Nuc
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tion efficiency was evaluated to 6.5% of the total BLG pro-
duction. As shown on the corresponding Western blot
analysis (Fig. 3), only the mature form of LEISS-Nuc-BLG
protein was secreted. Moreover, 46% of LEISS-Nuc-BLG
protein exhibited a native conformation, showing thus
that presence of Nuc does not influence the BLG folding
since similar proportion of the native form was measured
with LEISS-BLG. In the Cs fraction, proportion of the
native form was even improved compared to LEISS-BLG
since 8% of the fusion protein exhibited the BLG native
form. Nevertheless, most of the LEISS-Nuc-BLG synthe-
sized was located in the Ci fraction and intracellular
LEISS-Nuc-BLG concentration was about 2.5-fold lower
than intracellular LEISS-BLG concentration. As revealed
by Western blot analysis (Fig. 3), accumulation of precur-
sor SPUsp45-LEISS-Nuc-BLG in cell lysates resulted also in
Table 2: Quantitative assays of BLG in different fractions of recombinant L. casei strains
Fractionb Concentration of BLG (μg/L)a
BL23 + pNZ9520c BL23(int:nisRK)d
pSEC-Nuc pCYT:BLG pSEC:BLG pSEC:LEISS-BLG pSEC:LEISS-Nuc-BLG pSEC:LEISS-Nuc-BLG
S (% BLGn)e ndf 1.4 ± 2.2 (43%) 1.4 ± 1.8 (0%) 8.7 ± 2.3 (40%) 27 ± 3.7 (46%) 29.4 ± 6.4 (46%)
Cs (% BLGn) nd 57.6 ± 10.3 (27%) 57.6 ± 27.3 (1%) 38.4 ± 12 (1%) 44.1 ± 12 (8%) 57.7 ± 6.3 (8%)
Ci nd 19.2 ± 2.6 647.4 ± 301.1 975 ± 238.1 342.9 ± 128.7 526.9 ± 131.4
Total nd 78.2 ± 6.5 706.4 ± 303.9 1022.1 ± 327.5 413.9 ± 116 613.9 ± 144.1
a Values represent the means ± SD of at least three independent experiments; b S, supernatant; Cs, soluble cytoplasmic fraction; Ci, insoluble 
cytoplasmic fraction; c L. casei BL23 cells transformed with pNZ9520 plasmid; d L. casei BL23 cells with nisRK genes integrated in the chromosome; e 
Percentage of BLG in its native form; f nd, not detectable.
Expression cassettes for production and secretion of staphylococcal nuclease and/or bovine β-lactoglobulin Figure 1
Expression cassettes for production and secretion of staphylococcal nuclease and/or bovine β-lactoglobulin. 
Nuc, staphylococcal nuclease, BLG, bovine β-lactoglobulin, PnisA, nisin-inducible lactococcal promoter; RBS, ribosome binding 
site of usp45 gene; SPUsp45, signal peptide of Usp45, LEISS, secretion-enhancer propeptide LEISSTCDA.
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the presence of signals of lower molecular mass, certainly
as a consequence of proteolytic degradation of misfolded
recombinant protein.
Taken together, modifications used to improve BLG pro-
duction in L. lactis are also effective in L. casei. Although
BLG production in L. casei remains 2 to 10-fold lower
than that obtained in L. lactis [8], we succeeded to obtain
a substantial increase in BLG production and secretion. In
both L. casei and L. lactis, the highest yield was obtained
with the LEISS-Nuc-BLG form. While in L. lactis the opti-
mal secretion was obtained with the LEISS-BLG form, the
highest level of secretion in L. casei was reached with the
LEISS-Nuc-BLG construct. Use of the two-plasmid NICE
system resulted also in a 500-fold increase in BLG produc-
tion compared to the level obtained with recombinant L.
casei strains possessing one copy of the blg gene into their
chromosome [14]. However, Western blot analysis of Nuc
production (Fig. 2, lane 0) or LEISS-Nuc-BLG production
(Fig. 3, first lane) revealed that the NICE system is rela-
tively leaky in the absence of nisin induction. BLG pro-
duction was then further optimized by investigating the
conditions of nisin induction.
Integration of nisRK genes into the L. casei chromosome
It has already been observed that the two-plasmid NICE
system is less tightly regulated in Lactobacillus strains than
in L. lactis strains [21,22]. In order to strengthen the regu-
lation and to prevent the toxicity due to high expression
levels of the nisin regulatory genes, the nisRK genes were
integrated into the BL23 chromosome, as described by
Pavan et al ([21], see Materials and Methods). Competent
cells of the resulting strain, BL23(int:nisRK), were trans-
formed with the pSEC:LEISS-Nuc-BLG and intracellular
BLG productions with or without nisin induction were
analyzed by Western blot. As observed on Fig. 3, no LEISS-
Nuc-BLG synthesis was detected in the absence of nisin,
suggesting an improved regulation of the NICE system.
Compared to BL23 co-transformed with pSEC:LEISS-Nuc-
BLG and pNZ9520 plasmids, a 50% increase in BLG con-
centration was measured in the Ci fraction but neither
concentration of soluble LEISS-Nuc-BLG, nor proportion
of the native form in S and Cs fractions, were significantly
improved (Table 2).
Improved production of soluble BLG in L. casei
Recombinant L. casei are currently tested as delivery vehi-
cle of BLG to the gastrointestinal tract of mice. Such exper-
iments require high amounts of lactobacilli. Considering
that addition of nisin at early growth phase resulted in a
significant growth inhibition, different protocols allowing
overnight production of bacterial biomass and nisin
induction of L. casei cultures at higher cell density were
tested. Consequently, bacterial pellets from overnight cul-
tures were resuspended in fresh medium in order to
remove lactic acid and other bacterial metabolites (proto-
LEISS-Nuc-BLG production and secretion by L. casei BL23 and BL23 (int:nisRK) strains Figure 3
LEISS-Nuc-BLG production and secretion by L. casei BL23 and BL23 (int:nisRK) strains. Protein extracts were ana-
lyzed by immunoblotting using a specific anti-BLG monoclonal antibody for BL23 samples and rabbit polyclonal anti-Nuc anti-
bodies for BL23 (int:nisRK) samples, as described in the Materials and Methods section. Arrows indicate the positions of LEISS-
Nuc-BLG and precursor form.
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col B, see Materials and Methods). After 1 h 30 at 37°C to
restart bacterial growth, nisin induction was performed
and maintained for 2 h at 37°C.
Interestingly, 74% of intracellular BLG obtained with pro-
tocol B remained soluble when only 10% of intracellular
BLG obtained with the previously used protocol A were
located in the Cs fraction (Table 3). Although total BLG
yield with protocol B was nearly 2-fold lower, soluble BLG
concentration was about 4-fold higher than that obtained
with protocol A. The higher proportion of soluble BLG
was certainly due to a lower growth rate at the time of
induction. As already observed in E. coli [23-25], the fold-
ing capacity of the cell could become limiting at high
expression rates. A slower rate of heterologous gene
expression could then reduce inclusion bodies formation.
However, it should be noted that, although proportion of
soluble BLG is drastically enhanced, less than 1% of solu-
ble BLG was detected in its native conformation. Since
administration of L. lactis producing almost exclusively
denatured BLG could partially prevent mice from sensiti-
zation [6,9], conformation of the recombinant BLG
seemed not to be critical to induce a protective immune
response. On the other hand, considering the processing
of lactobacilli and their intracellular content by the host
immune system, higher concentrations of soluble antigen
could be advantageous for the development of a specific
immune response by favoring antigen presentation to the
mucosal immune system.
Conclusion
We observed that fusion of the LEISS propeptide and Nuc,
as initially described in L. lactis, improved both BLG pro-
duction and secretion in L. casei. Furthermore, integration
of nisRK genes into the L. casei BL23 chromosome allowed
to strengthen nisin-dependent production of BLG and led
to higher yields of recombinant protein. As previously
mentioned in L. lactis, all these modifications did not
improve the proportion of soluble BLG in the intracellular
fraction [8]. Production of soluble BLG was nevertheless
improved by performing nisin induction on L. casei cul-
tures at higher cell density.
These recombinant strains were primarily designed to
evaluate the potential advantages of using probiotic lacto-
bacilli for the mucosal delivery of an antigen in a mouse
model of allergy. This raised different questions such as
whether we need in situ production and secretion of the
antigen to induce or modulate an immune response or
what is the most effective way of administration. In this
regard, we are currently testing the BLG-producing L. casei
for prophylactic and therapeutic treatments on mice, via
delivery of recombinant lactobacilli by oral and intranasal
administrations.
Methods
Bacterial strains and culture conditions
The bacterial strains used in this study are listed in Table
1. L. casei strains, derived from strain BL23 (ATCC 393
cured of plasmid pLZ15, [26]) were grown at 37°C in De
Man-Rogosa-Sharpe broth ([27], Difco, BD, Le Pont de
Claix, France). Plates were incubated in anaerobic jars for
2 days at 37°C in an Anaerocult A system (Merck). When
required, erythromycin (Merck, Darmstadt, Germany)
was added to the media at 5 μg/mL to select L. casei trans-
formants. For promoter induction, nisin (Sigma, St Louis,
MO, USA) was added at the required concentration (2.5–
50 ng/mL).
DNA manipulations
Purification of genomic DNA from L. casei was performed
using the NucleoSpin Tissue kit (Macherey-Nagel, Hoerdt,
France). Taq DNA polymerase was purchased from Taka-
raBio, Inc. (Otsu Shiga, Japan).
Plasmids and strain constructs
The plasmids used in this study are listed in Table 1. L.
casei was transformed by electroporation using a gene-
pulser apparatus (Bio-rad Laboratories, Richmond, Cali-
fornia) as previously described [28]. The pMEC10 plas-
mid was kindly provided by Dr. P. Hols. This plasmid,
unable to replicate in L. casei, was introduced in electro-
competent cells to integrate the nisRK  genes into the
genome of the BL23 strain [21]. Erythromycin-resistant
integrants were analyzed by PCR and tested for functional
Table 3: Quantitative assays of BLG in different fractions of BL23(int:nisRK):LEISS-Nuc-BLG
Fractionb Concentration (ng BLG/mg total protein)a
Protocol Ac Protocol Bc
Cs (% BLGn)d 725,8 ± 33,7 (8%) 2481,6 ± 407,2 (1%)
Ci 6573,6 ± 631,6 884,7 ± 283,4
Total 7299.4 ± 597.9 3366.8 ± 356.4
a Values represent the means ± SD of at least two independent experiments; b Cs, soluble cytoplasmic fraction; Ci, insoluble cytoplasmic fraction; c 
see nisin induction in Materials and Methods; d Percentage of BLG in its native form.Microbial Cell Factories 2007, 6:12 http://www.microbialcellfactories.com/content/6/1/12
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nisin-induction. One of these clones, designated as
BL23(int:nisRK), was further studied.
Nisin induction
Two protocols were used in this study. Protocol A was per-
formed for most experiments as follows: an overnight cul-
ture of L. casei BL23 was used to inoculate fresh medium
at an initial OD600 of 0.35. After 1 h 30 at 37°C, nisin was
added at the required concentration and strains were
grown for 4–5 h at 37°C until an approximate OD600 of 1.
Considering growth properties of the recombinant
strains, we observed no significant difference in growth
rates. L. casei cultures were thus harvested at similar expo-
nential growth phase. For protocol B, cells grown to sta-
tionary phase by overnight culture were centrifuged at
8,000 × g for 5 min at 20°C and resuspended in 2.5 vol-
umes of fresh medium. Optical density at 600 nm of L.
casei  cultures after resuspension in fresh medium was
around 2.5. After 1 h 30 at 37°C in order to reinitiate bac-
terial growth, strains were induced with 25 ng nisin/mL
for 2 h at 37°C. Optical density at 600 nm of L. casei cul-
tures was then around 5.
Western blot analysis
After nisin induction (as described above), L. casei cul-
tures (2 mL) were pelleted by centrifugation at 8,000 × g
for 5 min at 4°C. Secreted proteins in the supernatant (1.7
mL) were precipitated with trichloroacetic acid (15% final
concentration). After centrifugation at 18,000 × g for 30
min at 4°C, the resulting pellet was resuspended in 25 μL
of 50 mM NaOH and 25 μL of 2× Laemmli buffer. The cell
pellet was washed once and resuspended in 100 μL of 50
mM Tris-HCl pH 7.5, 5 mM EDTA. Cells were disrupted
with glass beads and 100 μL of 2× Laemmli buffer (sup-
plemented with 5% β-mercaptoethanol as reducing
agent) were added. Protein sample concentration was
adjusted to the cell density of the producing culture if
needed. Samples were loaded for SDS-PAGE analysis fol-
lowed by Western blotting using polyclonal anti-Nuc anti-
bodies or specific anti-BLG monoclonal antibody Blg-92R
[16].
Immunoassays
After nisin induction (as described above), cells were pel-
leted by centrifugation at 8,000 × g for 5 min at 4°C and
the supernatant (S) was collected. Cells were resuspended
in 50 mM Tris-HCl, pH7.5, 5 mM EDTA and cell density
was normalized according to OD600. The soluble cytoplas-
mic protein (Cs) was extracted by disrupting cells with
glass beads. After centrifugation (15,000 × g, 15 min,
4°C), the supernatant corresponding to the Cs fraction
was collected. The pellet was resuspended in 50 mM Tris-
HCl, pH7.5, 8 M urea, 100 mM dithiothreitol, for 1 h at
room temperature in order to solubilize BLG included in
aggregates. After centrifugation (15,000 × g, 15 min, 4°C),
the supernatant containing the resolubilized insoluble
cytoplasmic protein (Ci) was collected and dialyzed
against 20 mM Tris-HCl, pH 7.5. Amounts of the BLG
native (BLGn) and denatured (BLGd) forms in the S and
Cs fractions, and of resolubilized BLG from the Ci frac-
tion, were determined by immunoassays based on the use
of pairs of monoclonal antibodies specific to either the
native form or the reduced and carboxymethylated, i.e.
denatured, form of BLG [16]. Briefly, 96-well microtiter
plates (Maxisorp; Nunc, Roskilde, Denmark) were coated
with a first monoclonal antibody (mAb, capture anti-
body) specific for BLGn or BLGd. Then, 50 μL of sample
and 50 μL of tracer (second mAb labelled with acetylcho-
linesterase) were added. Native BLG and reduced and car-
boxymethylated BLG were used as standards for
quantification of BLGn and BLGd, respectively. After 18 h
of incubation at 4°C, the plates were extensively washed,
and solid-phase-bound AChE activity was measured by
the method of Ellman [29]. Intracellular BLG concentra-
tion was also calculated with respect to the total protein
determined by the BCA protein assay (Pierce Biotechnol-
ogy, Rockford, IL 61105, USA).
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